Coronary Aneurysms in the Setting of Kawasaki Disease with Two Different Evolutions


Department of Pediatric Cardiology, Centro Hospitalar de São João, Portugal

Submission: June 20, 2018; Published: August 21, 2018

*Corresponding author: Paulo Éden Santos, Centro Hospitalar de São João. Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal, Tel: 00351910914664; Email: edenforever@live.com.pt

Introduction

Luis Garrido-García et al. [1] reported the incidence of giant coronary aneurysms during the acute phase of Kawasaki disease was 8.1%, higher than that reported in studies from countries with a high prevalence of the disease. In 88.2% of the patients with giant coronary aneurysms, the diagnosis was made after 10 days of the onset of fever, and the longer duration of symptoms until diagnosis and treatment seems to be related to the development of giant coronary aneurysms (p < 0.000). Despite the importance of giant coronary artery aneurysms, there are a few studies evaluating risk factors for their development. In 2010, Sudo et al. described risk factors for developing giant coronary aneurysms and found that being younger than 1 year or older than 5 years, receiving a total dose of immunoglobulin > 2500 mg/kg, and the use of corticosteroids following the administration of intravenous immunoglobulin were risk factors for giant coronary aneurysms.

Nakamura et al. [2] reported that being younger than 1 year, having leucocytosis, having a low serum concentration of sodium, as well as having low haemoglobin and elevated alanine aminotransferase levels were risk factors for the development of giant coronary aneurysms.

A 16-years-old female, with no relevant pathological history, diagnosed with Kawasaki disease at age 3, an echocardiogram revealed coronary aneurysms on the 15th day of illness, intravenous immunoglobulin and acetylsalicylic acid was initiated. She was discharged after 34 days, referred to our outpatient clinics for the follow-up. Selective coronary angiography showed aneurysms of the anterior descending artery with 12 x 7mm diameter (Z score of > 4.3), common trunk with 5mm (Z score of > 7.4), anterior descending with 5mm (Z score of > 6.6), an aneurysm with 7mm of maximum diameter. Diffuse dilation of the right coronary artery with a diameter of 5mm. Initiated hypocoagulation with warfarin and maintained acetylsalicylic acid, and was discharged after the completion of the therapeutic. He's now 6 years-old, clinically well, and cardiac catheterization showed complete regression of a coronary aneurysm and he suspended warfarin but remains with acetylsalicylic acid in antiagregant dose.

Our patients had coronary aneurysms, some of them most serious complications of Kawasaki disease. Although rare, the occurrence of these aneurysms is important as they presence affects the prognosis of the disease [3]. The aetiology of Kawasaki disease remains unknown and it is not possible to establish strategies to prevent it. Therefore, efforts must focus on determining the risk factors for the development of the most serious outcomes in order to decrease morbidity and mortality in these patients. Thrombus can easily develop in the coronary aneurysms despite strict anticoagulant therapy and coronary arteries may be occluded suddenly [4]. Acute myocardial infarction can occur and is mainly caused by a fresh thrombus.

Treatment with corticosteroids, immunoglobulins and acetylsalicylic acid may reduce the incidence of cardiac complications in Kawasaki disease. Even though the disease has been continuously reported, the clinical features of Kawasaki disease in terms of cardiovascular surgical aspects were not sufficiently discussed. Percutaneous transluminal coronary angioplasty is indicated for localized severe stenotic lesions. Considering that our first patient remains asymptomatic regardless of the fact that having the coronary aneurysms, we suggested that these patients must have a close follow-up and a very aggressive anticoagulation therapy with multiple agents. Surgical intervention (e.g., coronary artery...
bypass) should be recommended for patients who have ischemic changes with multivessel disease in spite of maximal medical therapy [5].

**Funding**

No funding has supported this work.

**Competing Interests**

No competing interests associated with any of the authors.

**Ethical standards**

This article does not include any studies with human participants performed by any of the authors.

**References**